Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Verona Pharma Analyst Ratings and Price Targets | NASDAQ:VRNA | Benzinga
Verona Pharma PLC has a consensus price target of $58.13 based on the ratings of 8 analysts. The high is $93 issued by Wells Fargo on February 28, 2025. The low is $31 issued by BTIG on March 20, 2023. The 3 most-recent analyst ratings were released by Wells Fargo, HC Wainwright & Co., and Canaccord Genuity on February 28, 2025, February 28, 2025, and February 12, 2025, respectively. With an average price target of $80 between Wells Fargo, HC Wainwright & Co., and Canaccord Genuity, there's an implied 20.26% upside for Verona Pharma PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
HC Wainwright & Co.
Canaccord Genuity
Roth MKM
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Verona Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/28/2025 | Buy Now | 39.81% | Wells Fargo | Tiago Fauth42% | $74 → $93 | Maintains | Overweight | Get Alert |
| 02/28/2025 | Buy Now | 12.75% | HC Wainwright & Co. | Raghuram Selvaraju43% | $60 → $75 | Maintains | Buy | Get Alert |
| 02/12/2025 | Buy Now | 8.24% | Canaccord Genuity | Edward Nash66% | $44 → $72 | Maintains | Buy | Get Alert |
| 01/21/2025 | Buy Now | -9.8% | HC Wainwright & Co. | Raghuram Selvaraju43% | $42 → $60 | Reiterates | Buy → Buy | Get Alert |
| 01/10/2025 | Buy Now | 2.22% | Roth MKM | Boobalan Pachaiyappan67% | → $68 | Initiates | → Buy | Get Alert |
| 01/08/2025 | Buy Now | 11.24% | Wells Fargo | Tiago Fauth42% | $64 → $74 | Maintains | Overweight | Get Alert |
| 01/08/2025 | Buy Now | -14.31% | Truist Securities | Joon Lee78% | $44 → $57 | Reiterates | Buy → Buy | Get Alert |
| 11/05/2024 | Buy Now | -3.79% | Wells Fargo | Tiago Fauth42% | $50 → $64 | Maintains | Overweight | Get Alert |
| 11/05/2024 | Buy Now | -36.86% | HC Wainwright & Co. | Raghuram Selvaraju43% | $36 → $42 | Maintains | Buy | Get Alert |
| 11/05/2024 | Buy Now | -33.85% | Canaccord Genuity | Edward Nash66% | $37 → $44 | Maintains | Buy | Get Alert |
| 10/09/2024 | Buy Now | -33.85% | Truist Securities | Joon Lee78% | $38 → $44 | Maintains | Buy | Get Alert |
| 10/03/2024 | Buy Now | -24.83% | Wells Fargo | Tiago Fauth42% | → $50 | Initiates | → Overweight | Get Alert |
| 10/01/2024 | Buy Now | -45.88% | HC Wainwright & Co. | Raghuram Selvaraju43% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 09/17/2024 | Buy Now | -45.88% | HC Wainwright & Co. | Raghuram Selvaraju43% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2024 | Buy Now | -45.88% | HC Wainwright & Co. | Raghuram Selvaraju43% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 07/22/2024 | Buy Now | -44.38% | Canaccord Genuity | Edward Nash66% | $35 → $37 | Maintains | Buy | Get Alert |
| 07/01/2024 | Buy Now | -45.88% | HC Wainwright & Co. | Raghuram Selvaraju43% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2024 | Buy Now | -42.87% | Truist Securities | Joon Lee78% | $32 → $38 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | -47.38% | Canaccord Genuity | Edward Nash66% | $35 → $35 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | -45.88% | HC Wainwright & Co. | Raghuram Selvaraju43% | $32 → $36 | Maintains | Buy | Get Alert |
| 05/15/2024 | Buy Now | -51.89% | HC Wainwright & Co. | Raghuram Selvaraju43% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | -54.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $33 → $30 | Maintains | Buy | Get Alert |
| 04/16/2024 | Buy Now | -45.88% | Piper Sandler | Yasmeen Rahimi61% | $31 → $36 | Maintains | Overweight | Get Alert |
| 03/04/2024 | Buy Now | -51.89% | HC Wainwright & Co. | Raghuram Selvaraju43% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | -50.39% | Wedbush | Liana Moussatos77% | → $33 | Reiterates | Outperform → Outperform | Get Alert |
| 01/22/2024 | Buy Now | -51.89% | HC Wainwright & Co. | Raghuram Selvaraju43% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 12/29/2023 | Buy Now | -51.89% | HC Wainwright & Co. | Raghuram Selvaraju43% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2023 | Buy Now | -51.89% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $32 | Reiterates | Buy → Buy | Get Alert |
| 09/01/2023 | Buy Now | -47.38% | Canaccord Genuity | Edward Nash66% | → $35 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | Buy Now | -51.89% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $32 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2023 | Buy Now | -54.9% | Wedbush | Liana Moussatos77% | → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 06/27/2023 | Buy Now | -51.89% | Truist Securities | Joon Lee78% | → $32 | Reiterates | Buy → Buy | Get Alert |
| 06/27/2023 | Buy Now | -51.89% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $32 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2023 | Buy Now | -51.89% | Truist Securities | Joon Lee78% | $28 → $32 | Maintains | Buy | Get Alert |
| 06/02/2023 | Buy Now | -51.89% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $32 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | -50.39% | Canaccord Genuity | Edward Nash66% | $31 → $33 | Maintains | Below Average | Get Alert |
| 05/10/2023 | Buy Now | -51.89% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $32 | Reiterates | → Buy | Get Alert |
| 04/10/2023 | Buy Now | -51.89% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $32 | Reiterates | → Buy | Get Alert |
| 03/20/2023 | Buy Now | -53.4% | BTIG | Thomas Shrader44% | $26 → $31 | Maintains | Buy | Get Alert |
| 03/13/2023 | Buy Now | -51.89% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $32 | Reiterates | → Buy | Get Alert |
| 12/21/2022 | Buy Now | -51.89% | HC Wainwright & Co. | Raghuram Selvaraju43% | $30 → $32 | Maintains | Buy | Get Alert |
| 12/20/2022 | Buy Now | -57.91% | Truist Securities | Joon Lee78% | $20 → $28 | Maintains | Buy | Get Alert |
| 12/20/2022 | Buy Now | -60.91% | BTIG | Thomas Shrader44% | $17 → $26 | Maintains | Buy | Get Alert |
| 08/29/2022 | Buy Now | -54.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $25 → $30 | Maintains | Buy | Get Alert |
| 08/26/2022 | Buy Now | -53.4% | Piper Sandler | Yasmeen Rahimi61% | → $31 | Initiates | → Overweight | Get Alert |
| 06/17/2022 | Buy Now | -72.94% | Wedbush | Liana Moussatos77% | $25 → $18 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Verona Pharma (VRNA) stock?
The latest price target for Verona Pharma (NASDAQ:VRNA) was reported by Wells Fargo on February 28, 2025. The analyst firm set a price target for $93.00 expecting VRNA to rise to within 12 months (a possible 39.81% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Verona Pharma (VRNA)?
The latest analyst rating for Verona Pharma (NASDAQ:VRNA) was provided by Wells Fargo, and Verona Pharma maintained their overweight rating.
When was the last upgrade for Verona Pharma (VRNA)?
There is no last upgrade for Verona Pharma
When was the last downgrade for Verona Pharma (VRNA)?
There is no last downgrade for Verona Pharma.
When is the next analyst rating going to be posted or updated for Verona Pharma (VRNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on February 28, 2025 so you should expect the next rating to be made available sometime around February 28, 2026.
Is the Analyst Rating Verona Pharma (VRNA) correct?
While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a maintained with a price target of $74.00 to $93.00. The current price Verona Pharma (VRNA) is trading at is $66.52, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.